02448nas a2200253   4500008004100000024000700041245011300048210006900161260001700230300001200247490000700259520171800266653001701984653001202001653001302013653001602026653001402042653001602056653001102072100002502083700002502108700002102133856004002154       2022                        eng d  a1200aPathophysiological Electrolyte Changes Connoted via Antagonism of Serotonin Receptor in Experimental Animals0 aPathophysiological Electrolyte Changes Connoted via Antagonism o  cOctober 2022  a548-5520 v143 a<p class="rtejustify"><strong>Background:</strong> Atypical antipsychotics are a subclass of antipsychotics that have emerged primarily since the 1970s for the treatment of psychiatric disorders. They are sometimes referred to as second-generation antipsychotics (SGAs). Several atypical antipsychotics have received regulatory approval for the treatment of disorders such as bipolar disorder, schizophrenia, irritability in autism, and as adjunctive treatment for major depressive disorders. <strong>Objectives</strong>: The purpose of the following study was to evaluate the effect of two widely known atypical antipsychotics, aripiprazole, and risperidone, on pathophysiological fluctuations in electrolytes. Several other studies were based on the following ideas, which brought a variety of different perspectives. As can be seen in the following evaluation, although atypical antipsychotics reduce the chance of extrapyramidal symptoms, it leads to impairment of renal function and destruction of renal histo-morphology. <strong>Materials and Methods:</strong> Thirty rats (10 per group) were used for this study, control group received normal saline, aripiprazole group received 10mg/kg//day, and risperidone group received 20mg/kg//day. The duration of therapy was long up to 3 months. <strong>Results: </strong>the results confirmed that both drugs reduced plasma sodium and chloride concentration with no effects on plasma potassium and calcium concentration. Moreover, the histomorphology at microscopic level shown no defects after 3 months of therapy.<strong> Conclusion</strong>: the outcome confirmed no deleterious defects associated with aripiprazole and risperidone when used for 3 months.</p>
10aAripiprazole10aCalcium10aChloride10aElectrolyte10aPotassium10aRisperidone10aSodium1 aMahmood, Mohammed, D1 aYounes, Mohammed, A.1 aSaarti, Mohammed  uhttps://www.phcogj.com/article/1869